Analysis Of Income And Expense [Abstract]

Ascelia Pharma - Filing #689421

Concept	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue	—	—	– SEK	—	—	—	—	—	—	—	—	—	– SEK	—
Material income and expense [abstract]
Research and development expense	—	—	118 113 SEK	—	—	—	—	—	—	—	—	—	107 574 SEK	—
Finance income (cost)	—	—	13 851 SEK	—	—	—	—	—	—	—	—	—	8 425 SEK	—
Miscellaneous other comprehensive income [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations and hedges of net investments in foreign operations [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations	– SEK	718,000 SEK	718,000 SEK	– SEK	– SEK	718,000 SEK	– SEK	– SEK	– SEK	135,000 SEK	135,000 SEK	– SEK	135,000 SEK	– SEK
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income	– SEK	130 504 SEK	130 504 SEK	131 223 SEK	– SEK	718,000 SEK	– SEK	– SEK	– SEK	135,000 SEK	125 768 SEK	– SEK	125 768 SEK	125 903 SEK